Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) Overview 6 Therapeutics Development 7 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Products under Development by Stage of Development 7 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Products under Development by Therapy Area 8 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Products under Development by Indication 9 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Pipeline Products Glance 10 Early Stage Products 10 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Products under Development by Companies 11 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Therapeutics Assessment 13 Assessment by Monotherapy/Combination Products 13 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 17 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Companies Involved in Therapeutics Development 19 Eli Lilly and Company 19 Oncodesign SA 20 Oncomatryx Biopharma, S.L. 21 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drug Profiles 22 Antibody to Antagonise TGF Beta Receptor Type 2 for Oncology - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 ITD-1 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 OMTX-001 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Small Molecules to Antagonize Transforming Growth Factor Beta Receptor II for Oncology - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Dormant Projects 28 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Discontinued Products 29 TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Featured News & Press Releases 30 Nov 14, 2012: Small molecule makes heart cells out of stem cells 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32

List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Products under Development by Companies, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 13 Number of Products by Stage and Mechanism of Action, H2 2016 14 Number of Products by Stage and Route of Administration, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Eli Lilly and Company, H2 2016 19 Pipeline by Oncodesign SA, H2 2016 20 Pipeline by Oncomatryx Biopharma, S.L., H2 2016 21 Dormant Projects, H2 2016 28 Discontinued Products, H2 2016 29 List of Figures Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Assessment by Monotherapy/Combination Products, H2 2016 13 Number of Products by Stage and Mechanism of Actions, H2 2016 14 Number of Products by Routes of Administration, H2 2016 15 Number of Products by Stage and Routes of Administration, H2 2016 15 Number of Products by Molecule Types, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 17

Eli Lilly and Company Oncodesign SA Oncomatryx Biopharma, S.L.